DCP Midstream Announces Appointment of New Directors to DCP Midstream and to Its General Partner
Mar 02, 2017 13:30 pm UTC| Business
DENVER, March 02, 2017 -- DCP Midstream, LP (NYSE:DCP) today announced that in connection with the completion of the combination of Enbridge Inc. (TSX:ENB) (NYSE:ENB) (Enbridge) and Spectra Energy Corp. on February 27,...
Scotland’s STV Upgrades Avid Infrastructure with Next-Generation News Graphics
Mar 02, 2017 13:30 pm UTC| Business
BURLINGTON, Mass., March 02, 2017 -- Avid® (Nasdaq:AVID) today announced that STV, Scotland’s leading digital media brand, is deploying next-generation graphics solutions from the Avid Studio Suite. STV will optimize...
Onconova Therapeutics, Inc. to Present at Two Healthcare Conferences in March
Mar 02, 2017 13:30 pm UTC| Business
NEWTOWN, Pa., March 02, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that...
Purdue technology showcase highlights leading-edge technologies ready to license
Mar 02, 2017 13:30 pm UTC| Business
WEST LAFAYETTE, Ind., March 02, 2017 -- About 250 people packed the Herman and Heddy Kurz Purdue Technology Center for the recent Purdue Technology Showcase that featured dozens of pioneering innovations. The technology...
Parker IQAN® Connect Delivers Next-Generation Electro-Hydraulic Control and Asset Management
Mar 02, 2017 13:30 pm UTC| Business
CLEVELAND, March 02, 2017 -- Parker Hannifin Corporation (NYSE:PH), the global leader in motion and control technologies, today announced the launch of Parker IQAN® Connect, the latest innovation in motion control....
Histogenics Corporation to Announce 2016 Financial Results on March 16, 2017
Mar 02, 2017 13:30 pm UTC| Business
WALTHAM, Mass., March 02, 2017 -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its...
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint
Mar 02, 2017 13:30 pm UTC| Business
REDWOOD CITY, Calif., March 02, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a clinical pharmacokinetic...
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood